Literature DB >> 26150175

Factors Associated With and Outcomes After Ventricular Fibrillation Before and During Primary Angioplasty in Patients With ST-Segment Elevation Myocardial Infarction.

Reza Jabbari1, Bjarke Risgaard2, Emil L Fosbøl3, Thomas Scheike4, Berit T Philbert3, Bo G Winkel2, Christine M Albert5, Charlotte Glinge6, Kiril A Ahtarovski3, Stig Haunsø7, Lars Køber8, Erik Jørgensen3, Frants Pedersen3, Jacob Tfelt-Hansen7, Thomas Engstrøm2.   

Abstract

We aimed to assess the risk factors and outcome of ventricular fibrillation (VF) before and during primary percutaneous coronary intervention (PPCI) in patients with ST-segment elevation myocardial infarction. From 1999 to 2012, we consecutively enrolled 5,373 patients with ST-segment elevation myocardial infarction. In total, 410 of the patients had VF before and 88 had VF during PPCI. During a mean follow-up of 4.2 years, 1,196 subjects died. A logistic regression model identified younger age, anterior infarct, Killip class >I at admission, and a preprocedural Thrombolysis In Myocardial Infarction flow grade of 0 to I to be significantly associated with VF before PPCI, whereas inferior infarct, a preprocedural Thrombolysis In Myocardial Infarction flow grade of 0 to I, and Killip class >I at admission were significantly associated with VF during PPCI. All-cause mortality was evaluated using the Cox regression model. Compared with the patients without VF, those with VF before or during PPCI had a significantly increased 30-day mortality, with an adjusted hazard ratio = 3.40 (95% confidence interval 1.70 to 6.70) and 4.20 (95% confidence interval 1.30 to 13.30), respectively. Importantly, there was no tendency of 30-day mortality difference between VF before and during PPCI (p = 0.170). In patients with VF before or during PPCI who survived for at least 30 days, there was no increase in the long-term mortality. In conclusion, our data suggest that 30-day mortality is the same for patients with VF before PPCI compared with VF during PPCI, and the occurrence of VF before or during PPCI was associated with increased 30-day mortality but not with long-term mortality.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26150175     DOI: 10.1016/j.amjcard.2015.05.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  We must identify patients at risk for pre-hospital sudden cardiac arrest at the early phase of myocardial infarction.

Authors:  Santiago Montero; Alain Combes; Matthieu Schmidt
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Pharmacological blockade of small conductance Ca2+-activated K+ channels by ICA reduces arrhythmic load in rats with acute myocardial infarction.

Authors:  Laura A Hundahl; Stefan M Sattler; Lasse Skibsbye; Jonas G Diness; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Pflugers Arch       Date:  2017-03-11       Impact factor: 3.657

3.  Impact of the angiographic burden on the incidence of out-of-hospital ventricular fibrillation in patients with acute myocardial infarction.

Authors:  Yoichiro Sugizaki; Toshiro Shinke; Tomohumi Doi; Nobuaki Igarashi; Hiromasa Otake; Hiroyuki Kawamori; Ken-Ichi Hirata
Journal:  Heart Vessels       Date:  2018-07-13       Impact factor: 2.037

Review 4.  Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction.

Authors:  Charlotte Glinge; Stefan Sattler; Reza Jabbari; Jacob Tfelt-Hansen
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

5.  A Common Variant in SCN5A and the Risk of Ventricular Fibrillation Caused by First ST-Segment Elevation Myocardial Infarction.

Authors:  Reza Jabbari; Charlotte Glinge; Javad Jabbari; Bjarke Risgaard; Bo Gregers Winkel; Christian Juhl Terkelsen; Hans-Henrik Tilsted; Lisette Okkels Jensen; Mikkel Hougaard; Stig Haunsø; Thomas Engstrøm; Christine M Albert; Jacob Tfelt-Hansen
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

6.  Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model.

Authors:  Stefan M Sattler; Anniek F Lubberding; Lasse Skibsbye; Reza Jabbari; Reza Wakili; Thomas Jespersen; Jacob Tfelt-Hansen
Journal:  J Cardiovasc Transl Res       Date:  2019-01-07       Impact factor: 4.132

Review 7.  Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models.

Authors:  Stefan Michael Sattler; Lasse Skibsbye; Dominik Linz; Anniek Frederike Lubberding; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Front Cardiovasc Med       Date:  2019-11-05

8.  Seasonality of ventricular fibrillation at first myocardial infarction and association with viral exposure.

Authors:  Charlotte Glinge; Thomas Engstrøm; Sofie E Midgley; Michael W T Tanck; Jeppe Ekstrand Halkjær Madsen; Frants Pedersen; Mia Ravn Jacobsen; Elisabeth M Lodder; Nour R Al-Hussainy; Niels Kjær Stampe; Ramona Trebbien; Lars Køber; Thomas Gerds; Christian Torp-Pedersen; Thea K Fischer; Connie R Bezzina; Jacob Tfelt-Hansen; Reza Jabbari
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

9.  Ischemic Postconditioning Reduces Reperfusion Arrhythmias by Adenosine Receptors and Protein Kinase C Activation but Is Independent of KATP Channels or Connexin 43.

Authors:  Emiliano Raúl Diez; Jose Antonio Sánchez; Natalia Jorgelina Prado; Amira Zulma Ponce Zumino; David García-Dorado; Roberto Miguel Miatello; Antonio Rodríguez-Sinovas
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

10.  Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With ST-Segment-Elevation Myocardial Infarction.

Authors:  Mia Ravn Jacobsen; Reza Jabbari; Charlotte Glinge; Niels Kjær Stampe; Jawad Haider Butt; Paul Blanche; Jacob Lønborg; Olav Wendelboe Nielsen; Lars Køber; Christian Torp-Pedersen; Frants Pedersen; Jacob Tfelt-Hansen; Thomas Engstrøm
Journal:  J Am Heart Assoc       Date:  2020-02-12       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.